Metabolic Syndrome (MS) is recognized as a cluster of cardiovascular risk factors. All components of MS have a genetic base. Genes of the renin angiotensin system are potential candidate genes for MS. We investigated whether angiotensin converting enzyme (ACE) gene polymorphism increases susceptibility to MS as an entity in a Mexican population. In a cross-sectional study, 514 individuals were studied including 245 patients with MS and 269 subjects without MS criteria. ACE gene polymorphism was detected using PCR. MS was defined according to The National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) criteria, except that the raised fasting plasma glucose ≥ 100 mg/dl criterion for identification of intolerance fasting glucose was modified in accordance with the suggestion of the American Diabetes Association. Patients with MS were significantly different from subjects without MS in relation to mean body mass index (BMI), waist circumference (WC), systolic blood pressure, diastolic blood pressure, glucose, total cholesterol (C), triglycerides, HDL-C, and LDL-C (P ＜ 0.0001). The differences in the mean BMI, WC, glucose, total cholesterol, triglycerides, LDL-C, and HDL-C were maintained in patients with the MS and DD genotypes (P ＜ 0.01). The DD genotype was strongly associated with MS (adjusted OR = 5.48, 95% CI 3.20-9.38, P ＜ 0.0001). We concluded that the DD genotype increases susceptibility to MS in a Mexican population. These results indicate that pharmacological and non-pharmacological treatment and a reduction in body fat will have important therapeutic implications in this disease.
Introduction
Metabolic Syndrome (MS) is recognized as a cluster of cardiovascular risk factors that frequently coincide with central obesity, dyslipidemia, hypertension, and hyperglycemia (Timar et al., 2000) with a frequent occurrence in various ethnic groups. Its presence is associated with a high risk of developing cardiovascular disease (CVD) (Isomaa et al., 2001) .
Association between angiotensin-1 converting enzyme gene polymorphism and the metabolic syndrome in a Mexican population
Recent estimates show the prevalence of MS in the adult population as 32% for Hispanic Americans, 22% for Afro-Americans, and 24% for Caucasian populations (Ford et al., 2002) . This prevalence increases more than 70% in patients with type 2 diabetes (Ilanne-Parikka et al., 2004) . All components of MS have a genetic base (Scott et al., 2000) . As a consequence, there is an interaction or multiplying effects of polymorphism in a growing number of genes potentially involved in this disease.
The renin angiotensin system (RAS) is a coordinated cascade that starts with the synthesis and secretion of renin from juxtaglomerular cells in the afferent renal artery (Boucher et al., 1977) . The angiotensin converting enzyme (ACE) key for RAS catalyzes the conversion of angiotensin I to angiotensin II (AngII), a potent vasocontrictor, and promotes the degradation of bradykinin (Erdos and Skidgel, 1987) . The insertion/deletion (I/D) polymorphism of the ACE gene is characterized by the presense (I) or absence (D) of an alu repetitive sequence of 287 bp in intron 16 of the ACE gene. Individuals with the insertion (I) have a fragment of 490 bp and individuals with the deletion (D) have a fragment of 190 bp in PCR amplification (Rigat et al., 1992) . The ACE gene is related to the inter-individual variability of plasma ACE levels. Individuals with the DD genotype have higher ACE plasma levels, compared with individuals with the II or I/D genotypes (Rigat et al., 1990) .
RAS is essential in cardiovascular hemodynamics and plays an important role in the development of CVD (Harrap, 1996) . Several studies have demonstrated that ACE gene polymorphism is a risk factor for ischemic cardiopathy (Ruiz et al., 1994) , hypertension (Caulfield et al., 1994) and type 2 diabetes (Feng et al., 2002) ; however, cross-sectional studies have yielded conflicting results depending on several factors, including ethnic differences, sample size, and patient characteristics (Cambien et al., 1994; Iwai et al., 1994; Panahloo et al., 1995; Chiu and McCarty, 1997) . Many studies have investigated the associations between genetic polymorphisms and the various components of MS. In contrast, few studies have explored this association with MS as an entity. Therefore, the aim of our study was to determine whether ACE polymorphism increases susceptibility to MS as an entity in a Mexican population.
Materials and Methods

Patients
Using a cross-sectional study from January 2005 to December 2005, we studied 514 individuals of both sexes including 245 patients with MS and 269 subjects without MS criteria. The sample size was calculated using a formula for cross-sectional studies with a confidence level of 95%, an acceptable error of ± 2.3%, and an expected proportion of patients with MS of 50% (Lwanga and Lemeshow, 1991) . The calculated sample size was 473 patients plus 10% additional to cover for possible lost. All patients were born in the state of Michoacán, which is located in the central part of Mexico. All were mestizos in origin as a result of admixture between Europeans and Native Mexicans. (Grundy et al., 2004) . MS was determined by the presence of at least three of the following abnormalities: central obesity (waist circumference ＞ 102 cm in men or ＞ 88 cm in women), triglycerides ≥ 150 mg/dl, or drug treatment for elevated triglycerides, HDL-C ＜ 40 mg/dl in men or ＜ 50 mg/dl in women or drug treatment for reduced HDL-C, blood pressure ≥ 130/85 mmHg without antihypertensive treatment or with antihypertensive drug treatment in a patient with a history of hypertension, and raised IFP ≥ 100 mg/dl or previously diagnosed type 2 diabetes. Diabetes was defined according to the American Diabetes Association criteria and hypertension was defined according to the Seven Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (DC report 2004; Chobanian et al., 2003) . 
Biochemical measurements
Glucose, total cholesterol, triglycerides, HDL-C, and LDL-C levels were measured in all subjects using equipment for chemical analysis (Dimension AR/ AVL Clinical Chemistry System, Newark, NJ).
Dyslipidemia was considered as a total cholesterol level of ≥ 200 mg/dl, triglyceride ≥ 150 mg/dl, low HDL-C ＜ 40 mg/dl for men and ＜ 50 mg/dl for women, and high LDL-C ≥ 130 mg/dl concentrations.
DNA analysis and PCR DNA was extracted from leucocytes obtained from peripheral blood samples of the subjects using the technique of Miller et al. (1988) with minor modifications.
Two hundred l of blood was placed in a 1.5-ml tube. Two hundred l SDS at 1.6% was added, the immersion was mixed, and 80 l of lysozyme (20 mg/ml) was added to the mixture and left for 20 min at 37 o C. Next, 290 l of ammonium acetate (7 M) was gently mixed and left for an additional 5 min. Then, 770 l of phenol was added, the tube was shaken vigorously and centrifuged at 10,000 rpm. The excess was placed in another 1.5-ml tube, 850 l absolute ethanol was added, the immersion was mixed, left for 5 min on ice, centrifuged at 10,000 rpm during 10 min, dried and dissolved once again in 50 l of DNA stabilizing solution. The concentration was determined spectrophotometrically at 260 nm and the integrity of the DNA was checked by agarose gel electrophoresis (1%) with 1×TAE buffer at 80 V and staining with ethidium bromide (0.5 g/ml).
PCR was performed at a final volume of 25 l with 100 ng of genomic DNA, 50 pmol of each oligonucleotide of the ACE gene with the following sequences: sense 5'-CTGGAGACCACTCCCATCCTT-TCT-3', antisense 5'-GATGTGGCCATCACATTCG-TCAGAT-3' (Asamoah et al., 1996) , 3 mM MgCl 2 , 2.5 l of 10× buffer (100 mM/l KCl, 100 mM/l Tris-HCl, pH 8.3), 2 l of the mixture of dNTPs (2.5 mM), 1 U of Taq polymerase and 25 l distilled, deionized water (cbp). Amplification was carried out in a thermocycler (Eppendorff, Mastercycler Gradient) with 30 cycles under the following conditions: 1 min at 94 o C for denaturation, 1 min at 58 o C for aligning and 2 min at 72 o C for extension, and a final extension at 72 o C for 5 min. To exclude mistyping of heterozygotes, all DD homozygote samples were confirmed using a pair of specific flanked oligonucleotides for insertion with the following sequences: sense 5'-TGGGACCACAGCGCCCGCCACTAC-3', antisense 5'-TCGCCAGCCCTCCCATGCCCATAA-3' (Shanmugan et al., 1993) . PCR products used were similar to the ones used for obtaining I/D except for the time and temperature of alignment, which was 45 s at 67 o C. PCR products were electrophoresed in 1% agarose gel and visualized by staining with ethidium bromide. Genotype II was characterized by a 490-bp band, genotype DD by a 190-bp band, and genotype ID by the presence of both bands.
Statistical analysis
Data are presented as mean ± SD. The HardyWeinberg equilibrium was estimated by comparing observed and expected genotype frequencies of ACE gene polymorphism using 2 . Differences between and within-groups of the continuous variables were analyzed using Student's t-test, ANOVA and Tukey's post hoc test, respectively. Nominal variables were analyzed using 2 . A multiple logistic regression model was used to test the effect of ACE genotypes on the likelihood of MS while controlling the confounding effects of age and gender. The odds ratio (OR) together with the 95% confidence interval (95% CI) for the allelic frequency in the study 
Results
A total 514 subjects was included, 245 patients with MS and 269 without MS criteria. Among the patients with MS, type 2 diabetes was found in 190 (77.6%), hypertension in 155 (63.3%), obesity in 138 (56.3%), and dyslipidemia in 90 (36.7%). In the subjects without MS, type 2 diabetes was found in 5 (1.9%), hypertension in 65 (24.2%), obesity 37 (13.8%), and dyslipidemia in 11 (4.1%). Table 1 shows the clinical and biochemical variables in individuals with and without MS. Patients with MS were significantly different from subjects without MS in relation to the mean BMI, WC, systolic blood pressure (SBP), diastolic blood pressure (DBP), glucose, total cholesterol, triglycerides, HDL-C, and LDL-C (P ＜0.0001). Differences in the mean BMI, WC, glucose, total cholesterol, triglycerides, HDL-C, and LDL-C, were maintained in patients with MS and the DD genotype in comparison with patients with The II genotype was considered as reference. *P ＜ 0.0001; **P = 0.01. Glucose (mg/dl) 164.5 ± 51.7 161.9 ± 50.3 187.3 ± 59.6* 83.6 ± 10.3 82.6 ± 11.5 84.3 ± 11.2
Total cholesterol (mg/dl) 228.9 ± 32.5 232.9 ± 47.0 260.5 ± 59.8* 213.4 ± 32.2 210.1 ± 38. MS and either the II or ID genotypes of ACE gene polymorphism (P ＜ 0.01, Table 2 ). Table 3 shows the distribution of the ACE genotype and allele frequencies in individuals with and without MS. The DD genotype (40.0% vs 16.0%, P ＜ 0.0001) and the D allele (62.7% vs 42.8%, P ＜ 0.0001) were significantly more frequent in patients with MS than without MS. In contrast, the II genotype (30.5% vs 14.7%, P ＜ 0.0001) was more frequent in subjects without MS than with MS. The distributions of the ACE genotypes observed were in agreement with the Hardy-Weinberg equilibrium. Table 4 shows the multiple logistic regression model adjusting for the confounding effects of gender and age. The results revealed a strong association of the DD genotype with MS (adjusted OR 5.48, 95% CI 3.20-9.38, P ＜ 0.0001). These results indicate that subjects with the DD genotype have an increased susceptibility for developing MS. Figure 1 shows representative gel images of the ACE gene.
Discussion
We examined the relationship between ACE gene polymorphism in 245 patients with MS and 269 subjects without MS using the ATP III criteria with modification in the IFG criteria in accordance with the American Diabetes Association's (Grundy et al., 2004) .
Our study reveals that the DD genotype is strongly associated with an increased susceptibility to MS as an entity. To our knowledge this is the first study that shows a relationship between ACE gene polymorphism with MS in a Mexican population. Our results are in accordance with a previous study in other populations (Lee et al., 2002) that has shown that the DD genotype confers an increased risk for MS. In a large Chinese population-based study with type 2 diabetes using the 1998 World Health Organization (WHO) criteria for diagnosis of MS, the DD genotype was associated with increased risks for MS, dyslipidemia, and albuminuria. In contrast, in other studies (Costa et al., 2002) performed in a Brazilian population of European ancestry selfclassified as white with type 2 diabetes and MS using the WHO criteria, an association between ACE gene I/D polymorphism and MS was not found. The reasons for this discrepancy is not known. One possible explanation is ethnic differences. It is well known that the allele frecuency of ACE gene polymorphism varies according to ethnic group (Barley et al., 1994) . The DD genotype is more frequent in a Caucasian population than in an Asian population. In the Mexican population, mestizas comprise 80% of the total, with 20% corresponding to Mexican Indian groups and a reduced group (less than 1.0%) of a white population formed by inmigrant Europeans (mainly Spanish) and North-Americans (from the United States of America and Canada). A Mexican mestizo has been defined by the National Institute of Anthropology as a person who was born in the country, has a Spanish-derived last name, and a family of Mexican ancestors of at least three generations (Gorodezky et al., 2001) . Our results support this hypothesis because a high prevalence of the DD genotype has been reported in previous studies in a Spanish population with nephropathy (Ortiz et al., 2003) . Another explanation may be related to possible interactions with other genes or enviromental factors, although further study is necessary to verify this explanation. Previously, Zhu et al. (2003) performed genotyping of single-nucleotide polymorphisms in the RAS genes ACE, angiotensinogen (AGT) angiotensin II receptor, subtype 1 (AGTR1), and renin in a biracial population sample. Evidence was found that inter-individual variation in the RAS genes contributes to a hypertension risk. Marre et al. (1997) studied the contribution of genetic polymorphism in RAS to the development of renal complications in insulin-dependent diabetes in a European population.
It is difficult to provide explanation of a mecha- nism by which ACE gene polymorphism promotes susceptibility to MS. One possible explanation is related to participation of RAS in the components of MS. It is generally accepted that RAS participates in the long-term complications of diabetes (Gilbert et al., 2003) and previous findings have reported an association of the DD genotype with the development of type 2 diabetes in several populations (Feng et al., 2002; Lee and Tsai, 2002; Ergen et al., 2004) . We found that patients with the MS and DD genotypes were associated with obesity. These results are interesting because of the strong association between RAS and the mechanisms of obesity. Obesity leads to hypertension and increases the cardiovascular risk (Mikhail et al., 1999) . RAS has been implicated in obesity by several authors (Giacchetti et al., 2002) , which is supported by recent investigations that show high plasma concentrations of angiotensinogen (ANG) (Umemura et al., 1997) and a rise in the expression of the ANG gene in obese humans (Van Harmelen et al., 2000) . The plasma ANG decrease was highly correlated with the WC decline and with one reduction in the systolic ambulatory blood pressure (Engeli et al., 2005) . These data suggest that a reduction in body weight can lead to a reduced RAS in plasma and adipose tissue. In addition, targeted expression of 11 -hidroxyesteroid dehydrogenase-1 (11--HSD1) in adipocytes and a direct relationship with obesity have been recently reported. In adipocytes, 11--HSD1 caused an increased plasma AGT level and increased blood pressure. In adipose tissue, the AGT gene was expressed in mice with a wild-type generic background (Alsaeid et al., 2004) . Higher ACE activity in obese individuals and a decrease in ACE activity with weight loss have been described previously (Keidar et al., 1994) as has the DD genotype predicting central obesity and an increase in body weight and blood pressure with aging in men (Keidar et al., 1996) . The DD genotype has influence on blood pressure and body weight.
Dyslipidemia in MS is characterized by an increase in triglycerides, LDL-C, and low HDL-C. These alterations contribute to an increase in the risk for CVD in individuals with MS. We found a relationship between dyslipidemia and ACE gene polymorphism with the DD genotype in patients with MS. This is related to previous studies that identified the DD genotype in patients with type 1 (Masuzaki et al., 2003) and type 2 diabetes (Lee and Tsai, 2002) , showing the important role of RAS as a likely contributor to MS. Experiments in vitro have suggested that ANG participates in the growth, development, and metabolic functioning of fatty tissue once it is converted into Ang II, which connects specifically to LDL-C (Harp et al., 2002) and produces another modified form of LDL-C that is captured by the macrophage. This provokes an accumulation of cholesterol (Strazzullo et al., 2003) .
Other possibility that may have significant clinical implications is the insulin resistance (IR) that appears to be a central feature of this syndrome associated with type 2 diabetes, obesity, dyslipidemia, hypertension, and recently with hypercoagulability, inflammation, atherosclerosis, and CVD (Dandona et al., 2002; Festa et al., 2002; Doelle, 2004) . RAS has been implicated in IR as RAS inhibits the metabolic actions of insulin and promotes its proliferative effects for cellular interactions with the signal transduction pathways. These pathways include the phosphatidylinositol 3 and MAPK pathways that are dependent on tyrosine phosphorylation of insulin receptor sustrates 1 and 2 after binding to their respective receptors (Prasad and Quyyumi, 2004) . However, the principal relationship between IR, ACE plasma levels, and the DD genotype in patients with MS requires more study in this and other populations.
In conclusion, we present evidence that the DD genotype of the ACE gene increases susceptibility to the MS entity in a Mexican population, providing genetic evidence of MS components in the Mexican population and an increased risk for CVD. These results indicate that pharmacological and non-pharmacological treatment and a reduction of body fat will have important therapeutic implications for this disease.
Additional studies will be necessary for investigating the association between the ACE gene and energy metabolism, vascular disregulation, the proinflamatory state, the prothrombothic state, and hormonal factors.
